PubRank

Adetola Kassim

Author PubWeight™ 16.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007 1.44
2 Multiple myeloma. J Natl Compr Canc Netw 2011 1.28
3 Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013 1.14
4 Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis 2006 0.94
5 Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant 2013 0.91
6 Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2012 0.90
7 Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw 2012 0.89
8 Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 2012 0.88
9 Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol 2011 0.87
10 Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010 0.86
11 Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 2011 0.85
12 Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp Hematol 2012 0.85
13 Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2011 0.83
14 Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009 0.83
15 Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood 2009 0.83
16 New allergies after cord blood transplantation. Cytotherapy 2013 0.82
17 Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw 2015 0.81
18 Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Exp Hematol 2012 0.79
19 Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017 0.75